Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 7Sarcoma 4Lymphoid 3Gastrointestinal 3Dermatologic 3Other hematologic neoplasm 2Genitourinary 2Thoracic 1Other solid neoplasm 1NET 1Head & Neck 1Gynecologic 1Endocrine 1Breast 1

Conditions

Melanoma 273Carcinoma, Non-Small-Cell Lung 49Carcinoma, Renal Cell 37Uveal Melanoma 23Skin Neoplasms 23Neoplasm Metastasis 23Colorectal Neoplasms 22Carcinoma, Transitional Cell 20Carcinoma, Merkel Cell 20Squamous Cell Carcinoma of Head and Neck 19Neoplasms 18Lung Neoplasms 17Carcinoma, Hepatocellular 16Brain Neoplasms 16Triple Negative Breast Neoplasms 14Uterine Cervical Neoplasms 13Ovarian Neoplasms 13Stomach Neoplasms 12Urinary Bladder Neoplasms 10Small Cell Lung Carcinoma 10Head and Neck Neoplasms 9Lymphoma 8Carcinoma, Basal Cell 8Pancreatic Neoplasms 7Esophageal Neoplasms 7Breast Neoplasms 7Kidney Neoplasms 6Sarcoma 5Prostatic Neoplasms 5Hodgkin Disease 5

Interventions

Cyclophosphamide 7Flow Cytometry 4fludarabine 3Therapeutics 3Polymerase Chain Reaction 3Nivolumab 3liposomal amphotericin B 2aldesleukin 2Voriconazole 2Psychiatric Rehabilitation 2Ondansetron 2Melphalan 2Itraconazole 2Ipilimumab 2Immunologic Techniques 2Etoposide 2Dexamethasone 2Caspofungin 2Carboplatin 2Calcium Dobesilate 2Busulfan 2Aprepitant 2Amplified Fragment Length Polymorphism Analysis 2Alemtuzumab 2tipifarnib 1sargramostim 1pembrolizumab 1lorukafusp alfa 1humanized 3F8 anti-GD2 monoclonal antibody 1fludarabine phosphate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Neuroblastoma × Nivolumab × Dermatologic × Clear all
NCT05302921 2025-01-01

Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors

Children's National Research Institute

Phase 2 Completed
5 enrolled
CNSDermatologicGastrointestinalGenitourinarySarcoma

Carcinoma, Hepatocellular, Melanoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma, Hepatoblastoma

NCT02304458 2023-10-17

Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas

National Cancer Institute (NCI)

Phase 1/2 Completed
140 enrolled 23 charts
CNSDermatologicLymphoidSarcoma

Hodgkin Disease, Lymphoma, Non-Hodgkin, Melanoma, Neuroblastoma, Rhabdomyosarcoma, Osteosarcoma, Neuroectodermal Tumors, Primitive, Peripheral

NCT04730349 2023-03-24

PIVOT IO 020

Bristol-Myers Squibb

Phase 1/2 Terminated
15 enrolled 14 charts
CNSDermatologicLymphoidOther hematologic neoplasmSarcoma

Ependymoma, Glioma, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Medulloblastoma, Melanoma, Neoplasms, Neuroblastoma, Recurrence, Rhabdomyosarcoma, Sarcoma, Ewing, Leukemia, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡